Spedox-6

PreclinicalSmall molecule

UUniversity of California, Irvine

Spedox-6 is one of 55 small molecule programs targeting Soft Tissue Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Soft Tissue SarcomaRecruiting

Soft Tissue SarcomaPreclinical

Recruiting

Competition

Competitive Landscape

64 competitors in Soft Tissue Sarcoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

34 2

Adriamycin

Pfizer

Phase 3

27 3

Idamycin

Pfizer

Approved

—4

Ifex

BBaxter Healthcare Corporation

Phase 3

32 5

Gemzar

Johnson & Johnson

Phase 3

11 6

Yondelis

AApotex Inc.

Phase 3

16 7

Neulasta

Amgen

Phase 3

3 8

Ellence

Pfizer

Phase 3

2 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

8 10

Keytruda

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

PreclinicalRecruiting

Soft Tissue Sarcoma

NCT07064018

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Recruiting·UUniversity of California, Irvine·Preclinical·NCT07064018·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Spedox-6. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spedox-6 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spedox-6. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Irvine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, Irvine

Spedox-6

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News